Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma

Citation

Gargett, T, Abbas, M, Rolan, P et al 2018, 'Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma', Cancer Immunology, Immunotherapy, vol. 67, pp. 1461-1472pp.

Year

2018

Field of Research

  • Tumour Immunology

Updated:  18 February 2020 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers